DiaMedica Therapeutics Inc (NAS:DMAC)
$ 2.88 0.03 (1.05%) Market Cap: 109.34 Mil Enterprise Value: 63.20 Mil PE Ratio: 0 PB Ratio: 2.36 GF Score: 36/100

Q3 2023 DiaMedica Therapeutics Inc Earnings Call Transcript

Nov 14, 2023 / 01:00PM GMT
Release Date Price: $2.5 (+6.84%)
Operator

(audio in progress) the time of any replay or transcript rereading. DiaMedica disclaims any duty to update its forward-looking statements. Following the prepared remarks, we will open the phone lines for questions. I would now like to introduce your host for today's call, Mr. Rick Pauls, DiaMedica's President and Chief Executive Officer. Mr. Pauls, you may begin, sir.

Rick Pauls
DiaMedica Therapeutics Inc. - President & CEO

Thank you, Paul. Hello, everyone, and welcome to our third quarter conference call. I'm joined this morning by Scott Kellen, our Chief Financial Officer.

Before we begin this morning, I want to take a moment to welcome Dr. Ambarish Shah as our Chief Technology Officer. Dr. Shah has over 25 years of experience in advancing biopharmaceuticals from early stage to commercialization, where he has had key contributions to over 50 drugs and multiple successful drug approvals. He was previously the Vice President and Head of Global Vaccine Development at CSL Seqirus, where he is accountable for end-to-end chemistry, manufacturing, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot